Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06900049RecruitingEarly Phase 1
Testing LE051 for boys with Duchenne muscular dystrophy (exon 51)
This study tests a new medicine called LE051 for boys with Duchenne muscular dystrophy (DMD) who have a specific genetic change that allows 'exon 51 skipping.' The goal is to see if it is safe and can help improve muscle function. Boys who join will be closely monitored for heart and lung health.
Shanghai, Shanghai MunicipalityAges 4–8 - NCT07238868RecruitingPhase 2
Long-term safety study of CB03-154 for epilepsy
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
Melbourne, VictoriaAges 18–70 - NCT07223138Enrolling by invitationPhase 3
Long-term safety study of sonelokimab for psoriatic arthritis
This study is for people who have already been in a previous trial of sonelokimab for psoriatic arthritis and want to continue treatment. It checks how safe and effective the medicine is over a longer time.
Avondale, ArizonaAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT07229638RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for solid tumors
This study tests a new drug called SHR-9839 given under the skin, combined with other anti-cancer treatments, for people with solid tumors. The goal is to see if it is safe and effective.
Nanjing, JiangsuAges 18–70 - NCT07213609RecruitingPhase 1/Phase 2
Study of GSK5460025 for advanced solid tumors
This trial tests a new drug, GSK5460025, alone or with other cancer treatments, for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help those whose cancer has a specific genetic feature (dMMR or MSI-H) or who have not responded to standard treatments.
Aurora, ColoradoAges 18 years+ - NCT07212933RecruitingPhase 2
RAK cell therapy for advanced stomach cancer
This trial tests a new type of immune cell therapy called RAK cells for people with late-stage stomach cancer that has spread and stopped responding to standard treatments. The goal is to see if it is safe and helps control the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07198555RecruitingPhase 1
Study of BBM-A101 for knee osteoarthritis
This trial tests a new medicine called BBM-A101 for people with moderate knee osteoarthritis. It aims to see if it is safe and helps reduce pain and improve function.
Shenzhen, GuangdongAges 40–75 - NCT07198659RecruitingEarly Phase 1
New immune cell therapy for advanced pancreatic cancer
This trial tests a new treatment using your own immune cells (called neutrophils) that are loaded with a drug to fight pancreatic cancer that cannot be removed by surgery. It may be an option if standard treatments have stopped working or caused bad side effects.
Xi’an, ShanxiAges 18–70 - NCT07185815RecruitingPhase 1/Phase 2
Study of a long-acting cariprazine shot for mood and schizophrenia
This trial tests a monthly injection of cariprazine (a medication for mental health conditions) in people who could benefit from it. It aims to see if the shot is safe, tolerable, and effective compared to taking pills every day.
AhmedabadAges 18–64 - NCT07181473RecruitingPhase 1
Safety of TJ101 for advanced solid tumors
This trial tests a new drug called TJ101 for people with advanced solid tumors who have tried standard treatments or have no standard options. It aims to see if the drug is safe and how well it works.
Orlando, FloridaAges 18 years+ - NCT07140900RecruitingPhase 1
Study of xaluritamig combined with hormone therapy for advanced prostate cancer
This trial tests a new drug, xaluritamig, given with standard hormone therapy for men with prostate cancer that has spread to other parts of the body (metastatic) and is still sensitive to hormone therapy. It aims to see if the combination is safe and works better than hormone therapy alone.
San Francisco, CaliforniaAges 18 years+ - NCT07137338RecruitingPhase 1
Gene therapy for BAG3-related dilated cardiomyopathy
This trial tests a one-time gene therapy called RP-A701 for people with dilated cardiomyopathy caused by a BAG3 gene mutation. The goal is to see if it is safe and can improve heart function.
San Diego, CaliforniaAges 18–65 - NCT07126873RecruitingPhase 1/Phase 2
Study of E-islet 01 for type 1 diabetes with severe low blood sugar
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07111325RecruitingPhase 1/Phase 2
iEVs injection for tennis elbow
This trial tests an injection called iEVs for people with tennis elbow (lateral epicondylitis) that hasn't gotten better with physical therapy or anti-inflammatory drugs. It aims to see if the treatment is safe and helps reduce pain.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02971358Recruiting
Surgery for very high-risk or limited-spread prostate cancer
This trial looks at how safe and how well early prostate surgery works for men with newly diagnosed very high-risk prostate cancer or a limited number of metastases (cancer spread). It may help some people live longer and control the cancer, but eligibility is very specific.
ViennaAges 18–75 - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07101640RecruitingPhase 1/Phase 2
Montelukast study for breathing problems in premature infants
This trial tests if the medicine montelukast can help very premature babies on breathing machines. It aims to see if it improves lung development and makes it easier for them to breathe on their own.
Little Rock, ArkansasAges 1 week–4 weeks - NCT07095127RecruitingPhase 2
Testing NVG-2089 for immune thrombocytopenia
This trial tests an investigational drug called NVG-2089 for adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets. The goal is to see if it safely raises platelet counts and improves bleeding symptoms.
Washington D.C., District of ColumbiaAges 18–80 - NCT07086521RecruitingPhase 1
Stem cell therapy for facioscapulohumeral muscular dystrophy
This trial tests a new stem cell treatment (ULSC) for people with FSHD, a type of muscular dystrophy. It aims to see if the treatment is safe and if it can help improve arm strength and daily movement.
Palo Alto, CaliforniaAges 15 years+ - NCT07094711RecruitingPhase 2
BCG vaccine boost for MAC lung disease
This study tests whether a single dose of the BCG vaccine (a live vaccine used for TB) can help the immune system fight MAC lung disease. Participants must not be on MAC treatment now, but may start it during the study if needed.
Charlottesville, VirginiaAges 18 years+ - NCT05182697Recruiting
Study of SCI-210 for autism-related behavior in kids
This trial tests SCI-210, a cannabis-based medicine, to see if it is safe and can improve challenging behaviors in children and young adults with autism. You may be asked to complete regular check-ins about behavior and development over the study.
BeershebaAges 5–18 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07077616RecruitingEarly Phase 1
Personalized vaccine for recurrent glioma
This trial tests a personalized vaccine created by AI to target your specific brain tumor. It is for people with a glioma that came back after standard treatments like surgery, radiation, or chemotherapy, and whose tumor has enough genetic mutations to make the vaccine.
ThessalonikiAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.